Prelude Therapeutics Incorporated (PRLD)
NASDAQ
Market Cap
$203.24M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
713 of 809
Rank in Industry
385 of 445
Largest Insider Buys in Sector
PRLD Stock Price History Chart
PRLD Stock Performance
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Insider Activity of Prelude Therapeutics Incorporated
Over the last 12 months, insiders at Prelude Therapeutics Incorporated have bought $0 and sold $0 worth of Prelude Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Prelude Therapeutics Incorporated have bought $42.86M and sold $3.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 900 shares for transaction amount of $4,779 was made by Vaddi Krishna (CEO) on 2023‑05‑25.
List of Insider Buy and Sell Transactions, Prelude Therapeutics Incorporated
| 2023-05-25 | Vaddi Krishna | CEO | 900 0.0019% | $5.31 | $4,779 | -27.80% | ||
| 2023-05-24 | Vaddi Krishna | CEO | 1,000 0.002% | $5.01 | $5,011 | -26.36% | ||
| 2023-05-24 | Lim Bryant David | Chief Legal Officer, Corp Sec. | 2,400 0.0053% | $5.39 | $12,936 | -26.36% | ||
| 2023-05-23 | Vaddi Krishna | CEO | 11,856 0.0257% | $5.63 | $66,749 | -30.28% | ||
| 2023-05-23 | Chardonnet Laurent | Chief Financial Officer | 5,000 0.0106% | $5.50 | $27,500 | -30.28% | ||
| 2023-05-22 | ORBIMED ADVISORS LLC | 869,565 1.9148% | $5.75 | $5M | -30.53% | |||
| 2023-05-22 | Bonita David P | 869,565 1.9148% | $5.75 | $5M | -30.53% | |||
| 2023-04-06 | Sale | Huang Jane | President, CMO | 13,280 0.0276% | $6.12 | $81,274 | -36.53% | |
| 2022-12-20 | Vaddi Krishna | CEO | 19,188 0.0417% | $5.13 | $98,446 | -6.63% | ||
| 2022-12-08 | Chardonnet Laurent | Chief Financial Officer | 10,000 0.0199% | $4.76 | $47,600 | -1.98% | ||
| 2022-06-01 | Chardonnet Laurent | Chief Financial Officer | 10,000 0.0213% | $4.23 | $42,300 | +48.69% | ||
| 2021-12-15 | Sale | Morosini Deborah | EVP, Chief of Clinical Affairs | 28,751 0.061% | $13.00 | $373,763 | -48.80% | |
| 2021-12-14 | Combs Andrew | EVP, Head of Chemistry | 4,000 0.0085% | $11.60 | $46,400 | -42.68% | ||
| 2021-12-13 | Combs Andrew | EVP, Head of Chemistry | 4,000 0.0087% | $12.12 | $48,480 | -43.56% | ||
| 2021-11-16 | Sale | Morosini Deborah | EVP, Chief of Clinical Affairs | 28,751 0.0619% | $15.88 | $456,532 | -54.90% | |
| 2021-10-05 | Sale | Mauro David J | Chief Medical Officer | 15,000 0.0336% | $30.96 | $464,350 | -74.15% | |
| 2021-09-07 | Sale | Mauro David J | Chief Medical Officer | 15,000 0.0314% | $36.69 | $550,283 | -77.25% | |
| 2021-09-02 | Sale | Pierce Christopher | EVP and Chief of Business Oper | 17,000 0.0396% | $41.68 | $708,493 | -77.31% | |
| 2021-08-27 | Sale | Scherle Peggy | Chief Scientific Officer | 6,014 0.0124% | $35.91 | $215,967 | -76.42% | |
| 2021-08-26 | Sale | Scherle Peggy | Chief Scientific Officer | 1,700 0.0038% | $35.19 | $59,819 | -74.05% |
Insider Historical Profitability
<0.0001%
| Bonita David P | 10119756 18.458% | $3.70 | 5 | 0 | +9.05% | |
| ORBIMED ADVISORS LLC | 10119756 18.458% | $3.70 | 5 | 0 | <0.0001% | |
| BAKER BROS. ADVISORS LP | 5212371 9.5071% | $3.70 | 4 | 0 | +34.76% | |
| Vaddi Krishna | CEO | 1067275 1.9467% | $3.70 | 4 | 0 | <0.0001% |
| Combs Andrew | EVP, Head of Chemistry | 268380 0.4895% | $3.70 | 3 | 0 | <0.0001% |
| Scherle Peggy | Chief Scientific Officer | 172920 0.3154% | $3.70 | 0 | 7 | |
| FRIEDMAN PAUL A | director | 152576 0.2783% | $3.70 | 1 | 0 | |
| Chardonnet Laurent | Chief Financial Officer | 42165 0.0769% | $3.70 | 3 | 0 | +5.48% |
| Huang Jane | President, CMO | 24220 0.0442% | $3.70 | 0 | 1 | |
| Dier Mardi | director | 10000 0.0182% | $3.70 | 1 | 0 | +34.76% |
| Pierce Christopher | EVP and Chief of Business Oper | 3750 0.0068% | $3.70 | 1 | 4 | +34.76% |
| Lim Bryant David | Chief Legal Officer, Corp Sec. | 2400 0.0044% | $3.70 | 1 | 0 | <0.0001% |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 444 0.0008% | $3.70 | 1 | 5 | +34.76% |
| Piper Brian | Chief Financial Officer | 0 0% | $3.70 | 0 | 2 | |
| Mauro David J | Chief Medical Officer | 0 0% | $3.70 | 0 | 10 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| OrbiMed | $51.71M | 19.86 | 10.91M | 0% | +$0 | 1.06 | |
| Baker Bros Advisors LP | $47.99M | 18.43 | 10.12M | 0% | +$0 | 0.6 | |
| Deerfield Management | $19.59M | 7.52 | 4.13M | 0% | +$0 | 0.38 | |
| Boxer Capital, LLC | $12.17M | 4.68 | 2.57M | 0% | +$0 | 0.61 | |
| BlackRock | $5.2M | 2 | 1.1M | +0.17% | +$8,934.90 | <0.0001 | |
| The Vanguard Group | $4.82M | 1.85 | 1.02M | +1.01% | +$48,077.83 | <0.0001 | |
| T. Rowe Price | $4.47M | 1.72 | 941,971 | -9.66% | -$477,743.96 | <0.01 | |
| Massachusetts Financial Services Co Ma | $2.41M | 0.93 | 508,149 | -0.51% | -$12,324.00 | <0.01 | |
| Geode Capital Management | $1.71M | 0.66 | 361,632 | +3.51% | +$58,143.10 | <0.0001 | |
| Sio Capital Management LLC | $1.52M | 0.58 | 320,394 | 0% | +$0 | 0.54 | |
| Morgan Stanley | $1.4M | 0.54 | 296,205 | -0.87% | -$12,281.33 | <0.0001 | |
| Renaissance Technologies | $1.16M | 0.45 | 244,800 | +13.12% | +$134,575.16 | <0.01 | |
| State Street | $1M | 0.39 | 211,441 | -0.37% | -$3,758.82 | <0.0001 | |
| Td Asset Management Inc | $761,490.00 | 0.29 | 160,652 | 0% | +$0 | <0.01 | |
| Charles Schwab | $603,734.00 | 0.23 | 127,370 | +2.14% | +$12,655.80 | <0.0001 | |
| Bridgeway Capital Management | $585,864.00 | 0.23 | 123,600 | -16.91% | -$119,206.26 | 0.01 | |
| Northern Trust | $578,977.00 | 0.22 | 122,147 | +7.05% | +$38,157.01 | <0.0001 | |
| Millennium Management LLC | $482,769.00 | 0.19 | 101,850 | +5.04% | +$23,150.16 | <0.0001 | |
| The Manufacturers Life Insurance Company | $342,522.00 | 0.13 | 72,262 | +2.99% | +$9,939.78 | <0.0001 | |
| Two Sigma Advisers LP | $332,748.00 | 0.13 | 70,200 | +13.59% | +$39,816.00 | <0.01 | |
| Goldman Sachs | $319,604.00 | 0.12 | 67,427 | -2.93% | -$9,660.12 | <0.0001 | |
| Exchange Traded Concepts, LLC | $302,824.00 | 0.12 | 63,887 | +44.91% | +$93,851.88 | 0.01 | |
| Two Sigma | $287,230.00 | 0.11 | 60,597 | +3.97% | +$10,963.63 | <0.0001 | |
| BNY Mellon | $189,922.00 | 0.07 | 40,068 | -20.81% | -$49,921.60 | <0.0001 | |
| Cerity Partners | $154,050.00 | 0.06 | 32,500 | New | +$154,050.00 | <0.0001 | |
| Bank of America | $152,931.00 | 0.06 | 32,264 | -13.94% | -$24,771.18 | <0.0001 | |
| Pale Fire Capital Se | $149,220.00 | 0.06 | 31,481 | -50.49% | -$152,154.06 | <0.01 | |
| Citadel Advisors LLC | $141,228.00 | 0.05 | 29,795 | -68.75% | -$310,635.24 | <0.0001 | |
| Kennedy Capital Management Inc | $118,666.00 | 0.05 | 25,035 | New | +$118,666.00 | <0.01 | |
| HSBC | $118,050.00 | 0.05 | 24,905 | +7.3% | +$8,034.32 | <0.0001 | |
| Acadian Asset Management | $104,000.00 | 0.04 | 22,110 | +42.69% | +$31,115.33 | <0.0001 | |
| RhumbLine Advisers | $100,318.00 | 0.04 | 21,166 | +3.74% | +$3,616.30 | <0.0001 | |
| New York State Common Retirement Fund | $95,000.00 | 0.04 | 20,122 | 0% | +$0 | <0.0001 | |
| Barclays | $97,000.00 | 0.04 | 20,387 | -33.21% | -$48,240.69 | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $95,113.00 | 0.04 | 20,066 | New | +$95,113.00 | <0.0001 | |
| State of Wisconsin Investment Board | $92,904.00 | 0.04 | 19,600 | -20.97% | -$24,648.00 | <0.0001 | |
| Zacks Investment Management | $87,484.00 | 0.03 | 18,457 | New | +$87,484.00 | <0.01 | |
| Nuveen | $79,618.00 | 0.03 | 16,797 | 0% | +$0 | <0.0001 | |
| Walleye Capital | $77,641.00 | 0.03 | 16,380 | New | +$77,641.00 | <0.0001 | |
| Jane Street Capital | $77,679.00 | 0.03 | 16,388 | -50.3% | -$78,631.74 | <0.0001 | |
| UBS | $74,205.00 | 0.03 | 15,655 | -21.23% | -$19,993.40 | <0.0001 | |
| Amundi | $52,047.00 | 0.03 | 15,130 | 0% | +$0 | <0.0001 | |
| Dimensional Fund Advisors | $67,805.00 | 0.03 | 14,305 | 0% | +$0 | <0.0001 | |
| Prelude Capital | $65,630.00 | 0.03 | 13,846 | -3.48% | -$2,370.00 | 0.01 | |
| Fidelity Investments | $54,747.00 | 0.02 | 11,550 | -95.64% | -$1.2M | <0.0001 | |
| American International Group | $34,758.00 | 0.01 | 7,333 | -0.86% | -$303.36 | <0.0001 | |
| JPMorgan Chase | $29,611.00 | 0.01 | 6,247 | -33.4% | -$14,850.53 | <0.0001 | |
| Wells Fargo | $24,999.00 | 0.01 | 5,274 | +14.68% | +$3,199.53 | <0.0001 | |
| Tower Research Capital | $15,864.00 | 0.01 | 3,347 | -16.16% | -$3,057.15 | <0.0001 | |
| Citigroup | $13,315.00 | 0.01 | 2,809 | +32.06% | +$3,232.76 | <0.0001 |